Chonnam Med J.  2017 Sep;53(3):229-230. 10.4068/cmj.2017.53.3.229.

Therapy-related Acute Myeloid Leukemia Following Treatment for Burkitt's Lymphoma

• Lee SS

• KMID: 2390438
• DOI: http://doi.org/10.4068/cmj.2017.53.3.229

Abstract

No abstract available.

MeSH Terms

Burkitt Lymphoma*
Leukemia, Myeloid, Acute*

Figure

• 

  FIG. 1 Microscopic images show a monotonous infiltrate of medium-sized lymphoid cells with round, non-cleaved nuclei (hematoxylin and eosin stain, ×200) (A) and a strong positivity (>99% of all malignant cells) in immunohistochemical stain for the cell proliferation marker Ki-67 (B). Bone marrow aspirate shows increased numbers of blasts with some cytoplasmic vacuoles and azurophilic granules (Wright stain, ×1,000) (C).

Reference

1. Sandler ES, Friedman DJ, Mustafa MM, Winick NJ, Bowman WP, Buchanan GR. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer. 1997; 79:1049–1054.

2. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993; 11:209–217.

3. Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. 2013; 121:2996–3004.

4. Zeichner SB, Arellano ML. Secondary adult acute myeloid leukemia: a review of our evolving understanding of a complex disease process. Curr Treat Options Oncol. 2015; 16:37.